Panelists said anticipating resistance mechanisms such as the C797S mutation or MET amplification is essential when designing first-line strategies. Selecting agents with favorable resistance profiles can prolong disease control and preserve future treatment options.
They outlined sequencing pathways and preferred approaches after progression on regimens including osimertinib or amivantamab–lazertinib. The panel emphasized that molecular reevaluation at progression is critical to guide subsequent therapies, whether targeted combinations or chemotherapy-based regimens.
Thoughtful sequencing can maximize overall survival while minimizing unnecessary toxicity. Planning enables clinicians to map multiline strategies that align with each patient’s molecular evolution and clinical needs.
Leave a Reply